Home » Stocks » TENX

Tenax Therapeutics, Inc. (TENX)

Stock Price: $2.31 USD -0.18 (-7.23%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
After-hours: $2.29 -0.02 (-0.87%) Jan 25, 7:47 PM
Market Cap 29.15M
Revenue (ttm) n/a
Net Income (ttm) -9.81M
Shares Out 12.43M
EPS (ttm) -1.11
PE Ratio n/a
Forward PE 17.79
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $2.31
Previous Close $2.49
Change ($) -0.18
Change (%) -7.23%
Day's Open 2.44
Day's Range 2.21 - 2.49
Day's Volume 1,115,695
52-Week Range 0.45 - 2.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 5 days ago

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) to host conf. call & live audio webcast on Jan 21, 2021, at 4:30 pm to discuss acquisition of PH Precision Med

Benzinga - 6 days ago

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-base...

Other stocks mentioned: ACRS, CYAD, GRTS, MRUS, NERV
InvestorPlace - 6 days ago

Tenax Therapeutics (TENX) stock is flying high on Tuesday after announcing it has acquired biotech company PH Precision Med. The post TENX Stock: 8 Things to Know About Tenax Therapeutics and ...

Business Wire - 6 days ago

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) acquires PH Precision Med (PHPM), adding imatinib to its pipeline. Stuart Rich, MD joins as CMO.

Business Wire - 2 months ago

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) today reported financial results for the third quarter 2020 and provided a business update

Business Wire - 2 months ago

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces HELP Study presented at American Heart Association (AHA) Scientific Sessions available Nov. 13th

Business Wire - 2 months ago

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) will host a virtual R&D webinar for analysts and investors on Wednesday, November 18, 2020 at 4:30 p.m. EST

Business Wire - 3 months ago

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces amendment to Orion License Agreement adding oral levosimendan.

Business Wire - 3 months ago

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces presentation of Phase 2 HELP Study at virtual meeting of HFSA on Saturday, Oct 3, 2020 @ 4:30 pm EDT

Business Wire - 4 months ago

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.

Business Wire - 4 months ago

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.

Business Wire - 5 months ago

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.

Business Wire - 6 months ago

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.

Business Wire - 6 months ago

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) Announces $8MM Registered Direct and PIPE Offering with single healthcare-focused institutional investor

Benzinga - 7 months ago

Shares of nano-cap Tenax Therapeutics Inc (NASDAQ: TENX), are advancing strongly Tuesday in the wake of a positive clinical readout.

About TENX

Tenax Therapeutics, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical... [Read more...]

Industry
Biotechnology
Founded
1967
CEO
Anthony DiTonno
Employees
9
Stock Exchange
NASDAQ
Ticker Symbol
TENX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for TENX stock is "Buy." The 12-month stock price forecast is 3.67, which is an increase of 58.87% from the latest price.

Price Target
$3.67
(58.87% upside)
Analyst Consensus: Buy